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ABSTRACT 
Introduction: Neurotrophic factors (NTFs) have been evaluated for neuroprotective effects 
in Parkinson's disease (PD). However, clinical trials examining the efficacy of intracerebral 
administration of NTFs on motor symptoms in PD have produced mixed results, and are thus 
inconclusive. The objective of this systematic review and meta-analysis was to determine the 
effects of intracerebral NTF application on motor symptoms in people with PD. 
Methods: We searched PubMed, MEDLINE, EMBASE, and Cochrane from inception 
through to March 31 2016 for open-label trials and randomized controlled trials (RCTs) 
which intracerebrally administered NTFs to PD patients, and which performed motor 
examination of Unified Parkinson’s Disease Rating Scale.  
Results: Eight studies with a total of 223 participants were included. Fixed effects analysis 
revealed that NTF treatment did not significantly reduce motor symptoms in PD patients 
compared to placebo controls (P = 0.98). Combining open-label and RCT data, both 
treatment with NTFs (P < 0.001) and treatment with placebo (P < 0.05) significantly 
improved motor function in PD patients when compared to predicted symptoms in untreated 
PD controls. Finally, random effects analysis revealed that NTF-treated PD patients were not 
significantly likely to improve following intracerebral NTF administration (P = 0.25). 
Conclusion: In conclusion, intracerebral NTF administration does not improve motor 
symptoms in PD patients, when compared to placebo-treated controls. These findings may 
guide therapeutic decisions and inform future research on NTFs and their application in PD.  
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INTRODUCTION 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, in which 
nigrostriatal dopaminergic (DA) neurons progressively degenerate to cause debilitating motor 
symptoms [1-5]. Despite decades of research, there is no disease-modifying therapy for PD 
[4-6]. Current symptomatic treatments improve quality of life and functional capacity, 
however their efficacy wears off over time and they cause disabling side-effects [6, 7]. Thus, 
there is an urgent need to develop new therapies that halt/reverse the neurodegeneration in 
PD. 
Neurotrophic factors (NTFs) are endogenous proteins critical for the development and 
maintenance of neurons [8]. Several NTFs promote the survival and growth of midbrain DA 
neurons in vitro and in vivo, while glial cell line-derived neurotrophic factor (GDNF) and 
neurturin (NTN) have been used in PD clinical trials [8-10]. These NTFs have been delivered 
to the PD brain via various delivery methods, to distinct target region(s), in small- and larger-
scale clinical trials. While initial open-label trials have demonstrated the feasibility and 
potential efficacy of NTFs in improving motor symptoms in PD patients, more recent clinical 
trials have had limited success. Despite this, in principle NTF therapy is still a promising 
disease-modifying therapy for PD, and remains an area of intense scientific research. To date 
however, a systematic review of the NTF trials in PD patients has not been published. Thus, 
the aim of this study was to conduct a systematic review and meta-analysis to quantitatively 
evaluate the effectiveness of intracranial NTF application in clinical trials on the motor 
symptoms of people with PD, in comparison to PD patients who did not receive NTF 
treatment. 
 
METHODS 
Study Design and Registration 
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The present systematic review and meta-analysis adhered to the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) statement [11], and is registered with 
PROSPERO (registration number CRD42016033889). 
 
Selection Criteria for Studies 
Study designs: 
Eligible studies included open-label trials and randomized controlled trials (RCTs) which 
were published in the English language. 
 
Participants: 
We included studies which examined people with PD. We did not make exclusions based on 
PD disease stage, age, gender or medication.  
 
Interventions: 
We included clinical trial studies in which PD patients received intracranial administration of 
NTFs. We included studies which administered NTFs to the brain (any region(s)), brain 
parenchyma and/or ventricular system. Studies administering NTFs peripherally, outside of 
the central nervous system, were not included as NTFs do not cross the blood-brain barrier. 
We did not exclude studies based on the method chosen to administer NTFs. We defined 
NTFs as proteins that are critical for the development and maintenance of neurons in the 
developing and adult brain, and we excluded any studies which administered molecules, 
compounds or proteins that did not meet this definition.  
 
Comparators: 
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Given the selective, yet broad, nature of participants chosen for this review, and the single 
therapeutic intervention of interest, we solely compared PD patients which had received 
intracranial NTF administration to control PD patients which did not receive intracranial NTF 
administration. We did not exclude studies based on the nature of the control treatment. 
 
Outcomes: 
The primary outcome measure for this systematic review was the assessment of motor 
symptoms of PD patients through motor examination using the Unified Parkinson’s Disease 
Rating Scale (UPDRS), in which a decrease in UPDRS score is indicative of improved PD 
symptoms. Studies which did not assess motor symptoms by use of the UPDRS score were 
excluded. All response rates were calculated as the mean response of all randomised patients. 
Improved or disimproved motor symptoms (lower or higher UPDRS score, respectively) 
served as a dichotomous outcome. When studies reported UPDRS scores at various-time 
points during a trial, we recorded the mean of those multiple values. Adverse effects that 
resulted in death at any point during or after the trial, as a direct result of the treatment 
intervention, were also recorded. Studies were not selected for inclusion or exclusion based 
on the length of follow-up of outcomes. No secondary outcomes were recorded. 
 
Search Strategy 
We searched PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of 
Controlled Trials from inception through to March 31, 2016 using a combination of the 
following MeSH search terms: Parkinson disease AND nerve growth factors AND clinical 
trial. To ensure literature saturation, we scanned the reference lists of included studies or 
relevant reviews identified through the search. We also searched the authors’ personal 
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literature databases to make sure that all relevant material was captured. The literature search 
was limited to studies in the English language.  
 
Data Collection and Analysis 
Selection of Studies: 
Two review authors (SH/GO’K) independently screened titles and abstracts of all studies 
identified through database searches in the citation library. Irrelevant studies were excluded. 
For the remaining studies which appeared to meet the inclusion criteria, the full text article 
was uploaded to the citation library, and two authors (SH/GO’K) independently applied the 
predefined selection criteria. We resolved any disagreement through discussion, and 
consultation with a third author (AS) when necessary. We recorded the reasons for exclusion.  
 
Data extraction and management: 
A form for standardised data extraction was designed and tested before two review authors 
(DL/AS) independently extracted data, which was subsequently verified by another 
independent reviewer (SH) to reduce errors and bias in data extraction. Data abstracted 
included all information of interest e.g. participant details, methodology, intervention details, 
and relevant patient outcomes. Reviewers resolved any disagreements by discussion, and one 
arbitrator (SH) adjudicated any unresolved disagreements. One review author (SH) collated 
and entered all data into Review Manager 5.3 (ReviewManager version 5.3, The Nordic 
Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). 
 
Assessment of risk of bias in included studies: 
Two review authors (DL/AS) assessed the risk of bias using the Cochrane risk of bias 
assessment tool outlined in chapter 8 of the Cochrane Handbook for Systematic Reviews of 
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Interventions, which classifies studies as having low, high, or unclear risk of bias in the 
following domains: selection bias, performance bias, detection bias, attrition bias, reporting 
bias, and carryover effect. Any disagreements were resolved first by discussion and then by 
consultation with a third author for arbitration (SH). One author (SH) computed graphic 
representations of potential bias within and across studies using Review Manager 5•3. 
 
Measures of Treatment Effect: 
The treatment effect for the primary outcome data was expressed as a pooled risk ratio (RR) 
with 95% confidence interval (CI). Studies with multiple treatment groups were combined 
into a single group, while missing data was sought from original authors if deemed necessary. 
The primary analysis was per individual randomised. 
 
Assessment of heterogeneity: 
Clinical heterogeneity was assessed by considering the variability in participant factors 
between trials (e.g. age) and trial factors (e.g. randomization concealment, blinding of 
outcome assessment, losses to follow-up, treatment type, co-interventions). We discussed 
clinical homogeneity, and based on this discussion, we decided whether pooling of data was 
appropriate. Statistical heterogeneity was tested using the Chi2 test (significance level: 0.1) 
and I2 statistic (0% to 40%: might not be important; 30% to 60%: may represent moderate 
heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: 
considerable heterogeneity). If high levels of heterogeneity among the trials existed (I2 
>=50% or P <0.1) the study design and characteristics in the included studies were explored.  
 
Data synthesis: 
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Each outcome was combined and calculated using the statistical software RevMan 5.3, 
according to the statistical guidelines referenced in the current version of the Cochrane 
Handbook for Systematic Reviews of Interventions. The Mantel-Haenszel method was used 
for the fixed effect model if tests of heterogeneity were not significant. When statistical 
heterogeneity was observed (I2 >=50% or P <0.1), the random effects model was chosen. No 
subgroup or subset analyses were performed within our participant group. 
 
Sensitivity analysis: 
The process of undertaking a meta-analysis involves making decisions about inclusion 
criteria. We used sensitivity analysis to explain high levels of clinical heterogeneity, and to 
assess the impact on the overall treatment effect of inclusion of trials which did not report an 
intention to treat analysis, had high rates of participant attrition, and/or had other missing 
data. 
 
Assessment of meta-bias(es): 
In order to determine whether publication/selection bias was present, we determined whether 
the protocol of the trial was published before recruitment of patients to the study was started. 
We then evaluated whether selective reporting of outcomes was present (outcome reporting 
bias) by comparing outcomes reported in the protocol and the published report. We compared 
the fixed effect estimate against the random effects model to assess the possible presence of 
small sample bias. 
 
Quality of the evidence: 
We used the Grading of Recommendations, Assessment, Development and Evaluation 
(GRADE) approach to assess the quality of evidence [12]. An initially assumed ‘high quality’ 
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of evidence was downgraded for meeting any of the following criteria: (1) risk of bias, (2) 
heterogeneity, (3) indirectness, (4) imprecision, and (5) publication/selection bias. 
 
RESULTS 
Search Results 
The search strategy yielded 244 records, of which 233 trials were excluded based on our 
exclusion criteria and 11 were retrieved in full text and assessed for eligibility [13-23]. 
Among the 11 potentially eligible studies, 2 full‐text articles were excluded; one for being an 
abstract of an ongoing study [22], and the other because the NTFs were co-applied with a cell 
transplant [20]. Two full-text articles were part of the same study [14, 21], and were thus 
combined for the meta-analysis. Eight studies were included in the systematic review and 
meta‐analysis (Figure 1A) [13-19, 21, 23]. 
 
Study Characteristics 
The eight eligible studies included a total of 223 participants. Participants included men and 
women between the ages of 35 and 75 years old who had moderate-to-severe PD for at least 5 
years. Five of the studies only included PD patients who had a good response to Levodopa, 
and motor complications that could not be satisfied with medical therapy [13, 14, 16, 17, 19, 
21]. All studies excluded patients which had medical conditions that may have compromised 
the study, e.g. dementia, abnormal Parkinsonism, and previous neurosurgery. Four trials 
administered GDNF [14, 15, 18, 21, 23], and four trials administered NTN [13, 16, 17, 19]. 
Five trials intracerebrally applied the chosen NTF to the putamen [14-17, 21, 23], one to the 
ventricular system [18], and two to both putamen and substantia nigra [13, 19]. Four trials 
directly infused the NTF [14, 15, 18, 21, 23], while four trials used viral vectors to deliver the 
NTF [13, 16, 17, 19]. 
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Risk of bias in included studies 
Figure 1B summarises the scores for the risk of bias assessment. Four of the included studies 
were RCTs [15, 16, 18, 19] and four were open-label trials [13, 14, 17, 21, 23]. The four 
RCTs were double-blinded, but the four open-label trials scored high risk for selection, 
performance, and detection biases [13, 14, 17, 21, 23]. Two of the RCTs scored high risk for 
attrition bias due to participant drop-out without explanation [16, 19]. One study scored 
unclear risk for other bias as the intended number of patients to be investigated was not 
completed due to an early end to the study [18]. 
 
Effects of interventions 
Fixed effects analysis of the four RCT [15, 16, 18, 19] revealed a pooled risk ratio (RR) of 
0.99 (95% confidence interval (CI) = 0.47–2.06), indicating that the overall effect did not 
significantly favour NTF treatment over placebo control in the reduction of motor symptoms 
(decrease in UPDRS score) in people with PD (P = 0.98) (Figure 2). The risk ratio for one of 
the RCTs [18] was not estimable as no improvements in motor symptoms were reported for 
either group. Heterogeneity between the included studies did not exceed that expected by 
chance (P = 0.59; I2 = 0%), implying that the results across the included studies were 
statistically homogeneous. 
 To analyse data from all eight trials, both open-label and RCTs, included for analysis 
in this review, PD patients who received a treatment (either intracerebral NTF application or 
placebo control) were compared to a predicted untreated control. The ‘predicted untreated PD 
control’ was the corresponding predicted outcome if the PD patient had not received 
treatment in the trial. Given the progressive neurodegenerative nature of PD [4, 24] and the 
fact that moderate-to-severe PD patients were included in these trials, all predicted controls 
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had no improvement in UPDRS score. In this meta-analysis, NTF treatment significantly 
improved motor symptoms in PD patients when compared to the predicted untreated PD 
control (RR = 11.00; 95% CI = 3.85–31.45; P < 0.001) (Figure 3A). Similarly, PD patients 
treated with a placebo had a significant improvement in UPDRS scores when compared to the 
predicted untreated PD control (RR = 7.67; 95% CI = 1.46–40.39; P < 0.05) (Figure 3B). 
Heterogeneity between the included studies for both meta-analyses did not exceed that 
expected by chance (P = 0.97; P = 0.61; I2 = 0%), implying that the results across the 
included studies were statistically homogeneous. 
 Finally, in order to assess the likelihood of motor symptoms improving in PD patients 
that had received intracerebral NTF administration, we compared the post-intervention 
UPDRS scores to baseline scores of NTF-treated patients. Due to statistical heterogeneity (P 
< 0.1; I2 = 86%), the random effects model was chosen for analysis and revealed that NTF-
treated PD patients were not significantly likely to have improved UPDRS scores following 
intracerebral NTF administration, when compared to the likelihood of no improvement (RR = 
0.47; 95% CI = 0.13–1.71; P = 0.25) (Figure 4). None of the eight studies that were evaluated 
reported severe adverse events that caused death as a result of the intervention. 
 
Quality of evidence across studies 
Using the GRADE criteria, we characterized the quality of evidence presented in the primary 
meta-analysis (Figure 2) as low. An initially-assumed high level of evidence was downgraded 
to moderate because less than 75% of the included studies were at low risk of bias across all 
domains. Furthermore, the imprecision of our primary meta-analysis (21 events and 190 
participants) resulted in a further downgrade of the quality of evidence to low. Despite the 
risk of bias and imprecision, our primary meta-analysis exhibited homogeneity and 
directedness (i.e. all participants were patients with PD), and it was free from selection bias 
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across included studies. The quality of evidence in the alternative meta-analyses (Figure 3, 4) 
was classified as very low as, in addition to the above downgrades, further downgrade(s) 
were made as these meta-analyses had selection bias and/or were indirect (predicted untreated 
controls) due to the inclusion of open-label trials. 
 
DISCUSSION 
The aim of this systematic review and meta-analysis was to evaluate the effectiveness 
of intracranial NTF application on the motor symptoms of people with PD. Our meta-analysis 
has found that intracranial NTF application does not significantly improve motor symptoms 
in people with PD, compared to placebo control-treated PD patients. The fixed effects 
analysis revealed a pooled RR of 0.99 (95% CI = 0.47–2.06), indicating an overall effect 
which did not significantly favour NTF treatment (P = 0.59). This finding was obtained from 
pooled analysis of four RCTs composed of 190 patients. However, it is important to stress 
that this should be interpreted with caution, due to the limited number of RCTs available for 
analysis. In addition to this, each of the four RCTs had a different treatment design, either in 
the NTF used, brain region(s) targeted and/or delivery method. Furthermore, using the 
GRADE criteria, the quality of evidence of this meta-analysis was characterized as low 
(further research is very likely to have an important impact on our confidence in the estimate 
of effect and is likely to change the estimate). In support of the pooled meta-analysis, lack of 
efficacy of NTFs in double-blind RCTs was reported in each of the four RCTs [15, 16, 18, 
19].  
 It is important to consider potential reasons for the lack of effectiveness of GDNF and 
NTN in these RCTs. A number of possibilities have been proposed. The first is that the lack 
of effectiveness can be primarily attributed to the late timing of the therapeutic intervention. 
There is robust evidence from the authors of the reviewed trials that retrograde transport of 
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GDNF/NTN to the substantia nigra is impaired in patients with moderate-to-severe PD; the 
very low levels of DA in the striata of patients after  >5 years of PD indicate that the disease 
has progressed significantly [19, 25-28]. Indeed, there is a profound loss of DA axons in the 
striata of PD patients at one year post diagnosis, and the innervating nigrostriatal DA axons 
are largely depleted by 4 years post diagnosis [26], highlighting the need for early 
intervention in PD. Such impaired axonal transport would severely reduce the amount of NTF 
that can reach the nigral DA cell bodies, and thus limit their neuroprotective effect [29]. 
Moreover, a post-hoc analysis has indicated that NTN has greater therapeutic benefits in PD 
patients evaluated <5 years after diagnosis [19]. Taken together, these findings suggest that if 
future trials are to take place, the recruitment of patients at an earlier disease stage, when the 
integrity of the nigrostriatal system is not so severely compromised, would be important. A 
second reason that has been proposed for the lack of efficacy of NTFs in PD clinical trials is 
that there may be inadequate bioavailability of NTFs in the PD striatum following their 
intracerebral administration [25, 27, 28, 30]. It has been reported that NTN has a poor 
diffusion profile in vivo, tipified by the fact that intrastriatal AAV2-NTN viral delivery 
resulted in NTN protein expression in only 15% of the striatal volume, with no NTN detected 
in the SN [28]. Despite this, the exact dose of NTFs applied, as well as the rapid 
internalisation of NTFs within neurons, is an important consideration when assessing NTF 
bioavailability in the PD brain [30, 31]. It is possible that limitations in the bioavailability and 
retrograde transport of NTFs in the brains of PD advanced patients impedes their 
neurotrophic effects on the remaining nigrostriatal DA neurons. 
A third potential explanation for the lack of effectiveness of GDNF and NTN in the 
RCTs comes from studies in animal models of PD, which have shown that these NTFs may 
not be able to signal in the PD brain. α-synuclein, the protein which pathologically 
accumulates in PD [4], has recently been shown to downregulate the expression of the 
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GDNF/NTN receptor, RET, in the α-synuclein rat model of PD, in which GDNF has failed to 
demonstrate neurotrophic effects [32, 33]. Indeed, the authors of the latest NTN trial [19] 
stated that “better results might be achieved with other trophic factors that are not RET 
dependent”. For example GDF5, which like GDNF/NTN is a member of the transforming 
growth factor β superfamily, is a RET-independent DA neurotrophic factor that signals via 
BMP receptors and Smad signalling to elicit neurotrophic effects in midbrain DA neurons in 
vitro and in vivo [8, 34, 35]. Moreover, other studies have shown that employing a 
combination of NTFs may be more beneficial than administering a single factor [36].  
Improving our understanding of the mechanisms of NTF action in the most disease-relevant 
models, and developing solutions to the potential issues of bioavailability, delivery and 
patient selection, will be critical for advancing this field. 
 Although no intervention-related deaths were identified in the studies included in this 
systematic review, concerns were raised with regards to less severe adverse effects, such as 
headaches, immune responses and other illnesses, which were not systematically reviewed 
herein. However, such milder adverse effects reported in the reviewed trials indicate that this 
neurosurgical procedure can be a burden to patients, which should be considered before the 
pursuit of further trials of this therapeutic approach in people with PD. We can conclude from 
these trials that intracranial application of NTFs is not a life-threatening therapeutic 
intervention.  
 To analyse data from all eight trials, both open-label and RCT, trial PD patients were 
compared to a predicted untreated control. The predicted untreated control were presumed to 
have no improvement in UPDRS score due to the progressive neurodegenerative nature of 
PD [4, 24], and because the patients that were included in these trials all exhibited moderate-
to-severe PD. In this meta-analysis, NTF treatment had a significant effect on motor 
symptoms when compared to the predicted untreated PD controls (RR = 11.00; 95% CI = 
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3.85–31.45; P < 0.001). However, it is important to note that this effect did not take into 
account any potential placebo effect. This finding was obtained from pooled analysis of eight 
trials composed of 149 patients. Using the same criteria for meta-analysis, placebo-treated PD 
patients were compared to the predicted untreated controls. In this meta-analysis, placebo 
control treatment also had a significant effect on motor symptoms when compared to the 
predicted untreated control (RR = 7.67; 95% CI = 1.46–40.39; P < 0.05). This finding was 
obtained from pooled analysis of four RCTs composed of 74 patients. Placebo-induced 
improvements on motor symptoms of PD patients have been reported in other clinical trials 
previously, with placebo treatment also being shown to increase DA release in the striatum of 
PD patients [37-40]. Thus, a significant dopamine-mediated placebo effect in PD patients 
may affect measurements of the effectiveness of novel treatments in RCTs. The findings of 
these meta-analyses should be interpreted with caution due to the low quality of evidence, the 
nature of the controls, and the well-documented significant placebo effect that PD patients 
experience in clinical trials.  
 Finally, in order to determine the probability of improved motor symptoms in PD 
patients that received intracerebral NTF application, UPDRS scores post-intervention were 
compared to those at baseline of NTF-treated patients. This finding was obtained from pooled 
analysis of eight trials composed of 149 patients, and the quality of evidence of this meta-
analysis was characterized as very low according to GRADE criteria. The pooled random 
effects analysis revealed that PD patients were not significantly likely to have improved 
UPDRS scores following intracerebral NTF application, when compared to the likelihood of 
no improvement (RR = 0.47; 95% CI = 0.13–1.71; P = 0.25). This finding may not be 
surprising considering the advanced disease stage of the PD patients included in these trials. 
Such information could be useful in informing treatment decisions for people with PD, and in 
deciding on inclusion criteria for the recruitment of PD patients for future clinical trials.  
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CONCLUSIONS 
The current evidence indicates that intracerebral NTF application does not improve motor 
symptoms for patients with PD compared to placebo controls. However, it is important to 
note that the conclusions of this meta-analysis are based on a small number of studies that 
are, by their nature, characterised by a small sample size, which increases the probability of a 
type II error (concluding that the treatment is not effective when in reality it is). The evidence 
also indicates that intracranial NTF administration is not a life-threatening procedure. Despite 
this, the ineffectiveness of GDNF and NTN in the RCTs to date suggests that NTF therapy 
may not warrant further clinical trials using its current intervention strategy and trial design. 
It also highlights a critical need for continuing preclinical research, with the aim of 
developing approaches for harnessing the survival- and growth-promoting actions of NTFs 
into a more targeted, robust, and less invasive, therapeutic strategy. These findings may guide 
therapeutic decisions and clinical trial design, and inform future research.  
 
ACKNOWLEDGEMENTS AND FINANCIAL DISCLOSURES 
Studies in the authors’ laboratories are supported by grants from the Irish Research Council 
(R15897; SVH/AS/G’OK), the National University of Ireland (R16189; SVH/AS/G’OK) and 
Science Foundation Ireland (15/CDA/3498; G’OK). This systematic review has no direct 
funder or sponsor. The funders indicated are not directly involved in any aspect of the 
systematic review and meta-analysis, but support the ongoing research output of the authors. 
 
AUTHORS ROLES 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
17 
 
AS is the guarantor. AS and SH are corresponding authors. SH, AS and GOK drafted the 
manuscript. All authors contributed to the development of the selection criteria, the risk of 
bias assessment strategy and data extraction criteria. SH, GOK and AS developed the search 
strategy. AS and DL both separately implemented the data extraction plan, and all authors 
contributed to the review of inclusions/exclusions and resolutions of disagreements (see 
methods for further details on this). SH provided statistical expertise and performed statistical 
analysis. SH, AS and GOK provided expertise on neurotrophic factor therapy for Parkinson’s 
disease. SH, AS and GOK constructed and approved the final manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
18 
 
REFERENCES 
[1] T. Pringsheim, N. Jette, A. Frolkis, T.D. Steeves, The prevalence of Parkinson's disease: a 
systematic review and meta-analysis, Mov. Disord. 29(13) (2014) 1583-1590. 
[2] R.F. Pfeiffer, Non-motor symptoms in Parkinson's disease, Parkinsonism Relat. Disord. 
22 Suppl 1 (2016) S119-122. 
[3] T. Gasser, Molecular pathogenesis of Parkinson disease: insights from genetic studies, 
Expert Rev Mol Med 11 (2009) e22. 
[4] A.J. Lees, J. Hardy, T. Revesz, Parkinson's disease, Lancet 373(9680) (2009) 2055-2066. 
[5] A. Toulouse, A.M. Sullivan, Progress in Parkinson's disease-where do we stand?, Prog. 
Neurobiol. 85(4) (2008) 376-392. 
[6] W. Oertel, J.B. Schulz, Current and experimental treatments of Parkinson disease: A 
guide for neuroscientists, J. Neurochem. 139 Suppl 1 (2016) 325-337. 
[7] C.W. Olanow, Levodopa/dopamine replacement strategies in Parkinson's disease--future 
directions, Mov. Disord. 23 Suppl 3 (2008) S613-622. 
[8] S.V. Hegarty, G.W. O'Keeffe, A.M. Sullivan, Neurotrophic factors: from 
neurodevelopmental regulators to novel therapies for Parkinson's disease, Neural. Regen. 
Res. 9(19) (2014) 1708-1711. 
[9] A.M. Sullivan, A. Toulouse, Neurotrophic factors for the treatment of Parkinson's disease, 
Cytokine Growth Factor Rev  22(3) (2011) 157-165. 
[10] M.J. Kelly, G.W. O'Keeffe, A.M. Sullivan, Viral vector delivery of neurotrophic factors 
for Parkinson's disease therapy, Expert Rev. Mol. Med. 17 (2015) e8. 
[11] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic 
reviews and meta-analyses: the PRISMA statement, PLoS Med. 6(7) (2009) e1000097. 
[12] D. Atkins, D. Best, P.A. Briss, M. Eccles, Y. Falck-Ytter, S. Flottorp, G.H. Guyatt, R.T. 
Harbour, M.C. Haugh, D. Henry, S. Hill, R. Jaeschke, G. Leng, A. Liberati, N. Magrini, J. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
19 
 
Mason, P. Middleton, J. Mrukowicz, D. O'Connell, A.D. Oxman, B. Phillips, H.J. 
Schunemann, T. Edejer, H. Varonen, G.E. Vist, J.W. Williams, Jr., S. Zaza, Grading quality 
of evidence and strength of recommendations, BMJ 328(7454) (2004) 1490. 
[13] R.T. Bartus, T.L. Baumann, J. Siffert, C.D. Herzog, R. Alterman, N. Boulis, D.A. 
Turner, M. Stacy, A.E. Lang, A.M. Lozano, C.W. Olanow, Safety/feasibility of targeting the 
substantia nigra with AAV2-neurturin in Parkinson patients, Neurology 80(18) (2013) 1698-
1701. 
[14] S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D.J. 
Brooks, C.N. Svendsen, P. Heywood, Direct brain infusion of glial cell line-derived 
neurotrophic factor in Parkinson disease, Nat. Med. 9(5) (2003) 589-595. 
[15] A.E. Lang, S. Gill, N.K. Patel, A. Lozano, J.G. Nutt, R. Penn, D.J. Brooks, G. Hotton, E. 
Moro, P. Heywood, M.A. Brodsky, K. Burchiel, P. Kelly, A. Dalvi, B. Scott, M. Stacy, D. 
Turner, V.G. Wooten, W.J. Elias, E.R. Laws, V. Dhawan, A.J. Stoessl, J. Matcham, R.J. 
Coffey, M. Traub, Randomized controlled trial of intraputamenal glial cell line-derived 
neurotrophic factor infusion in Parkinson disease, Ann. Neurol. 59(3) (2006) 459-466. 
[16] W.J. Marks, Jr., R.T. Bartus, J. Siffert, C.S. Davis, A. Lozano, N. Boulis, J. Vitek, M. 
Stacy, D. Turner, L. Verhagen, R. Bakay, R. Watts, B. Guthrie, J. Jankovic, R. Simpson, M. 
Tagliati, R. Alterman, M. Stern, G. Baltuch, P.A. Starr, P.S. Larson, J.L. Ostrem, J. Nutt, K. 
Kieburtz, J.H. Kordower, C.W. Olanow, Gene delivery of AAV2-neurturin for Parkinson's 
disease: a double-blind, randomised, controlled trial, Lancet Neurol. 9(12) (2010) 1164-1172. 
[17] W.J. Marks, Jr., J.L. Ostrem, L. Verhagen, P.A. Starr, P.S. Larson, R.A. Bakay, R. 
Taylor, D.A. Cahn-Weiner, A.J. Stoessl, C.W. Olanow, R.T. Bartus, Safety and tolerability of 
intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to 
patients with idiopathic Parkinson's disease: an open-label, phase I trial, Lancet Neurol. 7(5) 
(2008) 400-408. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
20 
 
[18] J.G. Nutt, K.J. Burchiel, C.L. Comella, J. Jankovic, A.E. Lang, E.R. Laws, Jr., A.M. 
Lozano, R.D. Penn, R.K. Simpson, Jr., M. Stacy, G.F. Wooten, Randomized, double-blind 
trial of glial cell line-derived neurotrophic factor (GDNF) in PD, Neurology 60(1) (2003) 69-
73. 
[19] C.W. Olanow, R.T. Bartus, T.L. Baumann, S. Factor, N. Boulis, M. Stacy, D.A. Turner, 
W. Marks, P. Larson, P.A. Starr, J. Jankovic, R. Simpson, R. Watts, B. Guthrie, K. Poston, 
J.M. Henderson, M. Stern, G. Baltuch, C.G. Goetz, C. Herzog, J.H. Kordower, R. Alterman, 
A.M. Lozano, A.E. Lang, Gene delivery of neurturin to putamen and substantia nigra in 
Parkinson disease: A double-blind, randomized, controlled trial, Ann. Neurol. 78(2) (2015) 
248-257. 
[20] L. Olson, E.O. Backlund, T. Ebendal, R. Freedman, B. Hamberger, P. Hansson, B. 
Hoffer, U. Lindblom, B. Meyerson, I. Stromberg, et al., Intraputaminal infusion of nerve 
growth factor to support adrenal medullary autografts in Parkinson's disease. One-year 
follow-up of first clinical trial, Arch. Neurol. 48(4) (1991) 373-381. 
[21] N.K. Patel, M. Bunnage, P. Plaha, C.N. Svendsen, P. Heywood, S.S. Gill, 
Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year 
outcome study, Ann. Neurol. 57(2) (2005) 298-302. 
[22] G. Paul, H. Widner, S. Palhagen, S. Rehncrona, G. Lind, B. Linderoth, H. Bjartmarz, K. 
Jansson, N. Herne, O. Zachrisson, A. Haegerstrand, P. Almqvist, Randomized, double-blind, 
placebocontrolled, safety-tolerability study of intracerebroventricular administration of 
sNN0031 (rhPDGF-BB) to patients with idiopathic Parkinson's disease (PD), using an 
implanted pump system: Ongoing clinical trial, European Journal of Neurology 17((Paul G.; 
Widner H.) Neurology, Lunds University Hospital, Lund, Sweden) (2010) 113. 
[23] J.T. Slevin, G.A. Gerhardt, C.D. Smith, D.M. Gash, R. Kryscio, B. Young, Improvement 
of bilateral motor functions in patients with Parkinson disease through the unilateral 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
21 
 
intraputaminal infusion of glial cell line-derived neurotrophic factor, J. Neurosurg. 102(2) 
(2005) 216-222. 
[24] J. Jankovic, Parkinson's disease: clinical features and diagnosis, J. Neurol. Neurosurg. 
Psychiatry 79(4) (2008) 368-376. 
[25] J.H. Kordower, A. Bjorklund, Trophic factor gene therapy for Parkinson's disease, Mov. 
Disord. 28(1) (2013) 96-109. 
[26] J.H. Kordower, C.W. Olanow, H.B. Dodiya, Y. Chu, T.G. Beach, C.H. Adler, G.M. 
Halliday, R.T. Bartus, Disease duration and the integrity of the nigrostriatal system in 
Parkinson's disease, Brain 136(Pt 8) (2013) 2419-2431. 
[27] R.T. Bartus, J.H. Kordower, E.M. Johnson, Jr., L. Brown, B.R. Kruegel, Y. Chu, T.L. 
Baumann, A.E. Lang, C.W. Olanow, C.D. Herzog, Post-mortem assessment of the short and 
long-term effects of the trophic factor neurturin in patients with alpha-synucleinopathies, 
Neurobiol. Dis. 78 (2015) 162-171. 
[28] R.T. Bartus, C.D. Herzog, Y. Chu, A. Wilson, L. Brown, J. Siffert, E.M. Johnson, Jr., 
C.W. Olanow, E.J. Mufson, J.H. Kordower, Bioactivity of AAV2-neurturin gene therapy 
(CERE-120): differences between Parkinson's disease and nonhuman primate brains, Mov. 
Disord. 26(1) (2011) 27-36. 
[29] K. Ito, H. Enomoto, Retrograde transport of neurotrophic factor signaling: implications 
in neuronal development and pathogenesis, J. Biochem. 160(2) (2016) 77-85. 
[30] X. Yi, D.S. Manickam, A. Brynskikh, A.V. Kabanov, Agile delivery of protein 
therapeutics to CNS, J. Control Release 190 (2014) 637-663. 
[31] D.J. Wolak, R.G. Thorne, Diffusion of macromolecules in the brain: implications for 
drug delivery, Mol. Pharm. 10(5) (2013) 1492-1504. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
22 
 
[32] M. Decressac, A. Ulusoy, B. Mattsson, B. Georgievska, M. Romero-Ramos, D. Kirik, A. 
Bjorklund, GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's 
disease, Brain 134(Pt 8) (2011) 2302-2311. 
[33] M. Decressac, B. Kadkhodaei, B. Mattsson, A. Laguna, T. Perlmann, A. Bjorklund, 
alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral 
dopamine neurons, Sci. Transl. Med. 4(163) (2012) 163ra156. 
[34] S.V. Hegarty, L.M. Collins, A.M. Gavin, S.L. Roche, S.L. Wyatt, A.M. Sullivan, G.W. 
O'Keeffe, Canonical BMP-Smad signalling promotes neurite growth in rat midbrain 
dopaminergic neurons, Neuromolecular Med. 16(2) (2014) 473-489. 
[35] S.V. Hegarty, A.M. Sullivan, G.W. O'Keeffe, BMP2 and GDF5 induce neuronal 
differentiation through a Smad dependant pathway in a model of human midbrain 
dopaminergic neurons, Mol. Cell. Neurosci. 56C (2013) 263-271. 
[36] J.D. Jaumotte, S.L. Wyrostek, M.J. Zigmond, Protection of cultured dopamine neurons 
from MPP(+) requires a combination of neurotrophic factors, Eur. J. Neurosci. 44(1) (2016) 
1691-1699. 
[37] R. de la Fuente-Fernandez, T.J. Ruth, V. Sossi, M. Schulzer, D.B. Calne, A.J. Stoessl, 
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease, 
Science 293(5532) (2001) 1164-1166. 
[38] S.C. Lidstone, Great expectations: the placebo effect in Parkinson's disease, Handb. Exp. 
Pharmacol. 225 (2014) 139-147. 
[39] S.C. Lidstone, M. Schulzer, K. Dinelle, E. Mak, V. Sossi, T.J. Ruth, R. de la Fuente-
Fernandez, A.G. Phillips, A.J. Stoessl, Effects of expectation on placebo-induced dopamine 
release in Parkinson disease, Arch. Gen. Psychiatry 67(8) (2010) 857-865. 
[40] C. McRae, E. Cherin, T.G. Yamazaki, G. Diem, A.H. Vo, D. Russell, J.H. Ellgring, S. 
Fahn, P. Greene, S. Dillon, H. Winfield, K.B. Bjugstad, C.R. Freed, Effects of perceived 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
23 
 
treatment on quality of life and medical outcomes in a double-blind placebo surgery trial, 
Arch. Gen. Psychiatry 61(4) (2004) 412-420. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
24 
 
FIGURE LEGENDS 
Figure 1: Study Flow Diagram and Risk of Bias Summary 
Figure 1: Study Flow Diagram and Risk of Bias Summary: (A) The search and selection procedure 
that was used for this systematic review and meta-analysis (adapted from [11]). (B) Review authors’ 
judgements about each risk of bias item for each included study. 
 
Figure 2: Effect of NTF Treatment on UPDRS Score Compared to Placebo Control 
Figure 2: Effect of NTF Treatment on UPDRS Score Compared to Placebo Control: Forest Plot of 
Comparison 1: Intracranial NTF administration compared to placebo control. Outcome 1,1: Improved 
UPDRS score (post-intervention). Meta-analysis of 4 RCTs composed of 190 patients. 
 
Figure 3: Effect of NTF Treatment or Placebo Control on UPDRS Score Compared to 
Predicted Control 
Figure 3: Effect of NTF Treatment or Placebo Control on UPDRS Score Compared to Predicted 
Control: (A) Forest Plot of Comparison 2: Intracranial NTF administration compared to predicted 
control. Outcome 2.1: Improved UPDRS score (post-intervention). Meta-analysis of 8 trials composed 
of 149 patients. (B) Forest Plot of Comparison 3: Placebo control compared to predicted control. 
Outcome 3.1: Improved UPDRS score (post-intervention). Meta-analysis of 4 RCTs composed of 74 
patients. 
 
Figure 4: Comparison of Improvement vs. No Improvement in UPDRS Score following 
NTF Intervention 
Figure 4: Comparison of Improvement vs. No Improvement in UPDRS Score following NTF 
Intervention: Forest Plot of Comparison 4: Improvement vs. No Improvement following NTF 
Intervention. Outcome 4.1: UPDRS score (post-intervention). Meta-analysis of 8 trials composed of 
149 patients. 
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HIGHLIGHTS 
• Intracranial neurotrophic factor application did not reduce motor symptoms in PD 
• NTFs and placebo improved UPDRS scores in PD over predicted scores in untreated PD 
• PD motor symptoms are not likely to improve after intracranial application of NTFs 
• Further studies are critical to advance the therapeutic application of NTFs for PD  
